Literature DB >> 2659380

Differential expression of CD25 and HC2 antigens on subtypes of acute myeloid leukemias.

M R Padrós1, M C Salamone, P A Zunszain, L Fainboim.   

Abstract

The presence of CD25 and HC2 antigens in 66 different patients with acute myeloid leukemia (AML) was investigated. The expression of both antigens was observed in 32% of AML cells. Dual fluorescence staining experiments performed in 5 AML patient cells showed that CD25 and HC2 antigens were simultaneously expressed in a single cell. The expression of both antigens was mainly observed in the M4 and M5 subtypes of AML. Although immunopurified IL-2 was able to block the binding of anti-CD25 monoclonal antibody to the AML cells, the IL-2 receptor did not appear to be functional.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2659380     DOI: 10.1111/j.1600-0609.1989.tb01467.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  2 in total

1.  CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

Authors:  John N Allan; Gail J Roboz; Gulce Askin; Ellen Ritchie; Joseph Scandura; Paul Christos; Duane C Hassane; Monica L Guzman
Journal:  Leuk Lymphoma       Date:  2017-07-18

2.  Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis.

Authors:  Kazunori Nakase; Kenkichi Kita; Taiichi Kyo; Takanori Ueda; Isao Tanaka; Naoyuki Katayama
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.